Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
EXELIXIS, INC. reported the year ended December 31, 2022 results: revenue $1,611.1 million, net income $182.3 million, EPS $0.56 per share, diluted.
- Period
- the year ended December 31, 2022
- Revenue
- $1,611.1 million
- Net income
- $182.3 million
- EPS
- $0.56 per share, diluted
- Result
- reported results
Exact text from the filing
Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
EXELIXIS, INC. reported the quarter ended December 31, 2022 results: revenue $423.9 million, net income $(30.2) million, EPS $(0.09) per share, basic and diluted.
- Period
- the quarter ended December 31, 2022
- Revenue
- $423.9 million
- Net income
- $(30.2) million
- EPS
- $(0.09) per share, basic and diluted
- Result
- reported results
Exact text from the filing
Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r
View on SEC.gov